This is an aggregated industry headline. Read the full story at PharmaVoice →
AstraZeneca aims for a new blockbuster run in cardio disease
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.
By PharmaVoice
· Jun 1, 2026
· via PharmaVoice
Image: PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Foundation Medicine has started the "Quality First" initiative to create awareness of how "not all cancer biom…
The WeekFierceBiotech ↗
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major…
The WeekPharmaceutical Technology ↗
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.…